Skip to main content


  • Poster presentation
  • Open Access

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment

  • 1,
  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7, 8,
  • 9 and
  • 1, 10
BMC Infectious Diseases201414 (Suppl 2) :P83

  • Published:


  • Hepatitis
  • Drug Interaction
  • Chronic Hepatitis
  • Therapeutic Drug Monitoring
  • Triple Therapy


BOC and TPV are potent NS3/4A protease inhibitors for the treatment of chronic hepatitis C (HCV) genotype 1 infection. BOC and TPV are both substrates and strong inhibitors of the CYP3A, therefore presenting a wide interindividual pharmacokinetic variability and multiple drug interactions especially with ARV such as lopinavir/r, darunavir/r or efavirenz, thus restricting options for concomitant ARV therapy. We evaluated plasma concentrations of coinfected and monoinfected patients treated with BOC and TPV and the PK data of patients treated with non recommended ARV.


Data from patients whose BOC and TPV trough concentration had been assessed during treatment were retrospectively analyzed. Plasma concentrations were determined using a LC-MS/MS method. Mann-Whitney U test was used for statistics (PASW Statistics 17).


Overall, 58 patients were included (84% male, median age: 51 years (34-70)), treated with BOC (25) or TPV (33). Thirty-two (55%) patients are coinfected (14 BOC, 18 TPV) and 26 (45%) are monoinfected (11 BOC, 15 TPV). Median (range, CV) TPV and BOC trough concentrations were respectively, 1928 ng/mL (92-3204, 47%) and 111 ng/mL (33-903, 112%) in coinfected patients versus 2787 ng/mL (252-5551, 54%) and 153 ng/mL (25-2658, 150%) in monoinfected patients, which is statistically different only for TPV (p<0.05). Six patients received non recommended ARV: 4 were treated with darunavir/r (2 BOC, 2 TPV), 1 with efavirenz and BOC and 1 with lopinavir/r and TPV. Median (range) TPV and BOC concentrations were respectively, 1967 ng/mL (580-3204) and 103 ng/ml (33-903) with recommended ARV versus 1304 ng/mL (92-2565) and 146 ng/ml (65-304) with non recommended ARV.


This study highlights a strong interindividual variability in BOC and TPV trough concentrations. Lower concentrations were observed in coinfected patients but remaining within the expected range, which may be explained by drug interactions with some ARV. Hence, therapeutic drug monitoring is useful to manage these interactions and evaluate the risk-benefit balance of using non recommended ARV in coinfected patients with advanced hepatic disease.

Authors’ Affiliations

Pharmacokinetics and toxicology department, Timone Hospital, Marseille, France
Infectious Diseases department, AP-HM Conception Hospital, Marseille, France
Hematology and Internal Medicine Department, Pays d’Aix Hospital, Aix-en-Provence, France
Medicine in prison department, AP-HM, Hôpitaux Sud, Marseille, France
Infectiology department, Sainte Musse Hospital, Toulon, France
Digestive surgery department, AP-HM Conception Hospital, Marseille, France
European Hospital, Marseille, France
Alphabio Laboratory, Marseille, France
Immuno-Hematology department, AP-HM Sainte-Marguerite Hospital, Marseille, France
INSERM UMR 911 - CRO2, Faculty of Pharmacy, University of Aix-Marseille, Marseille, France


© Chantry et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.